Generic Medicine Info
Indications and Dosage
Osteoarthritis, Rheumatoid arthritis
Adult: 10 mg once daily.

Adult: 20 mg bid.
Renal Impairment
Osteoarthritis,Rheumatoid arthritis:
<30Initiate with caution.
Hepatic Impairment
Child-Pugh scale 7-9: Initiate with caution. Child-Pugh scale >10: Avoid.
May be taken with or without food.
Hypersensitivity to sulfonamides, NSAIDs and other COX 2 inhibitors; asthma, urticaria; severe hepatic impairment; pregnancy (third trimester); lactation. Active GI bleed or ulceration, severe CHF, inflammatory bowel disease.
Special Precautions
Mild to moderate hepatic impairment; history of ulcer disease or GI bleeding; dehydration, hypertension, history of heart failure, left ventricular dysfunction, pre-existing oedema. Monitor Hb or haematocrit values for signs and symptoms of anaemia.
Adverse Reactions
Hypertension, back pain, myalgia, peripheral oedema, influenza-like symptoms, dizziness, headache, abdominal fullness, abdominal pain, diarrhoea, dyspepsia, flatulence, nausea, myalgia, sinusitis.
Potentially Fatal: Toxic epidermal necrolysis, exfoliative dermatitis.
PO: Z (NSAIDs caused foetal ductus arteriosus premature closure, foetal renal impairment and persistent pulmonary hypertension. Avoid near term, else use lowest dose for shortest time.), C
Drug Interactions
Concomitant admin of aspirin may result in an increased risk of GI ulceration and complications. It decreases the antihypertensive effect of antihypertensives e.g. ACE inhibitors. It increases plasma conc of dextromethorphan. It significantly decreases lithium serum clearance and renal clearance.
Description: Valdecoxib acts by selectively inhibiting prostaglandin synthesis primarily by blocking cyclooxygenase (COX-2) enzyme. It was withdrawn worldwide in April 2005, following risk of serious skin reactions and cardiovascular side effects.
Onset: 60 min.
Absorption: Peak plasma concentrations after 2.25-3 hrs (oral).
Distribution: Protein-binding: 98%
Metabolism: Extensively hepatic.
Excretion: Urine (as metabolites); 8-11 hrs (elimination half-life).
Store below 30°C.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Disclaimer: This information is independently developed by MIMS based on Valdecoxib from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in